Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1E | P49674 | 9/20 | 0.38 |
| ▸ | CSNK1D | P48730 | 6/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.35 |
| ▸ | DCLRE1B | Q9H816 | 1/20 | 0.34 |
| ▸ | DHODH | Q02127 | 2/20 | 0.34 |
| ▸ | TACR3 | P29371 | 2/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4343214 | 0.89 | CSNK1E (0.35) | CSNK1ECSNK1DADORA3ADORA2AADORA2B | |
| SCHEMBL4334488 | 0.83 | PTGER1 (0.37) | CSNK1ECSNK1DADORA3ADORA2AADORA2B | |
| SCHEMBL4340947 | 0.83 | PTGER1 (0.36) | CSNK1ECSNK1DPTGER1DCLRE1BDHODH | |
| SCHEMBL4341004 | 0.83 | PTGER1 (0.36) | CSNK1ECSNK1DADORA1PTGER1DCLRE1B | |
| SCHEMBL4334606 | 0.82 | PTPN11 (0.41) | CSNK1ECSNK1DPTGER1TACR3 | |
| SCHEMBL4339201 | 0.80 | JAK2 (0.38) | CSNK1ECSNK1DPTGER1DCLRE1BDHODH | |
| SCHEMBL4340976 | 0.80 | MAPT (0.38) | CSNK1ECSNK1DPTGER1TACR3 | |
| SCHEMBL4332493 | 0.79 | IKBKB (0.36) | JAK2JAK3 | |
| SCHEMBL4346820 | 0.78 | PTGER1 (0.40) | CSNK1ECSNK1DPTGER1DCLRE1BDHODH | |
| SCHEMBL4331950 | 0.76 | CTSA (0.37) | CSNK1ECSNK1DPTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7541376-B2 | 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-02 | — | — | US | disclosed |
| US-20050282880-A1 | Novel 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282880-A1 | Novel 1H-indazole compounds | MAPK1, MAPK3, MAPK13 | CSNK1E 202/4885CSNK1D 134/4885ADORA3 1577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.